Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124189 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
A Phase 1 study, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00124189 is a Phase 1 study that has completed, run by Geron Corporation. The registered enrollment target is 48 participants.
The verdict
NCT00124189, a Phase 1 study, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease.
Interventions
- DRUG GRN163L
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00124189
The ClinicalTrials.gov registry entry for NCT00124189 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GRN163L is the first listed.
NCT00124189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00124189 about?
NCT00124189 is a clinical study titled "Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)". The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease.
What is the current status of trial NCT00124189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2005-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00124189?
The interventions under investigation include: GRN163L (DRUG).
Who is sponsoring clinical trial NCT00124189?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.